Does the media favor ENOV or TLSI?

In the previous week, Enovis and Enovis both had 6 articles in the media. Enovis' average media sentiment score of 0.05 beat TriSalus Life Sciences' score of -0.13 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TLSI or PRCT?

In the previous week, PROCEPT BioRobotics had 2 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 8 mentions for PROCEPT BioRobotics and 6 mentions for TriSalus Life Sciences. PROCEPT BioRobotics' average media sentiment score of 0.16 beat TriSalus Life Sciences' score of -0.13 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PROCEPT BioRobotics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CBLL or TLSI?

In the previous week, CeriBell and CeriBell both had 6 articles in the media. CeriBell's average media sentiment score of 0.65 beat TriSalus Life Sciences' score of -0.13 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NNNN or TLSI?

TriSalus Life Sciences has a consensus price target of $10.20, indicating a potential upside of 151.23%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 TriSalus Life Sciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger earnings & valuation, NNNN or TLSI?

Anbio Biotechnology has higher earnings, but lower revenue than TriSalus Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 77.52 $6.40M N/A N/A TriSalus Life Sciences $45.08M 5.55 -$39.23M -$1.30 N/A

Is NNNN or TLSI more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A TriSalus Life Sciences -62.59% N/A -64.47%

Does the media prefer NNNN or TLSI?

In the previous week, TriSalus Life Sciences had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 2 mentions for Anbio Biotechnology. TriSalus Life Sciences' average media sentiment score of -0.13 beat Anbio Biotechnology's score of -0.63 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anbio Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TLSI or BBNX?

In the previous week, Beta Bionics had 32 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 38 mentions for Beta Bionics and 6 mentions for TriSalus Life Sciences. Beta Bionics' average media sentiment score of 0.05 beat TriSalus Life Sciences' score of -0.13 indicating that Beta Bionics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 33 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TriSalus Life Sciences (TLSI) Competitors

$4.06 -0.07 (-1.69%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.02 (+0.59%)

As of 10/9/2026 07:47 PM Eastern

Compare

TLSI vs. ENOV, PRCT, CBLL, NNNN, and BBNX

Should you buy TriSalus Life Sciences stock or one of its competitors? TriSalus Life Sciences's main competitors and comparable companies include Enovis (ENOV), PROCEPT BioRobotics (PRCT), CeriBell (CBLL), Anbio Biotechnology (NNNN), and Beta Bionics (BBNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TriSalus Life Sciences compare to Enovis?

Enovis (NYSE:ENOV) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

TriSalus Life Sciences has lower revenue, but higher earnings than Enovis. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.45	-$1.18B	-$19.26	N/A
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A

Enovis currently has a consensus target price of $39.50, suggesting a potential upside of 122.92%. TriSalus Life Sciences has a consensus target price of $10.20, suggesting a potential upside of 151.23%. Given TriSalus Life Sciences' higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Enovis has a net margin of -47.96% compared to TriSalus Life Sciences' net margin of -62.59%. Enovis' return on equity of 12.03% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
TriSalus Life Sciences	-62.59%	N/A	-64.47%

In the previous week, Enovis and Enovis both had 6 articles in the media. Enovis' average media sentiment score of 0.05 beat TriSalus Life Sciences' score of -0.13 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enovis has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

98.5% of Enovis shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Enovis beats TriSalus Life Sciences on 10 of the 15 factors compared between the two stocks.

How does TriSalus Life Sciences compare to PROCEPT BioRobotics?

TriSalus Life Sciences (NASDAQ:TLSI) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, PROCEPT BioRobotics had 2 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 8 mentions for PROCEPT BioRobotics and 6 mentions for TriSalus Life Sciences. PROCEPT BioRobotics' average media sentiment score of 0.16 beat TriSalus Life Sciences' score of -0.13 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

TriSalus Life Sciences has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

TriSalus Life Sciences has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A
PROCEPT BioRobotics	$337.34M	3.12	-$95.57M	-$1.94	N/A

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 4.0% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PROCEPT BioRobotics has a net margin of -32.53% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%

TriSalus Life Sciences currently has a consensus price target of $10.20, indicating a potential upside of 151.23%. PROCEPT BioRobotics has a consensus price target of $25.50, indicating a potential upside of 38.59%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
PROCEPT BioRobotics	2 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.31

Summary

TriSalus Life Sciences and PROCEPT BioRobotics tied by winning 8 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to CeriBell?

CeriBell (NASDAQ:CBLL) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

TriSalus Life Sciences has lower revenue, but higher earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	10.18	-$53.41M	-$1.76	N/A
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A

2.6% of TriSalus Life Sciences shares are held by institutional investors. 17.7% of CeriBell shares are held by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TriSalus Life Sciences has a net margin of -62.59% compared to CeriBell's net margin of -64.73%. TriSalus Life Sciences' return on equity of 0.00% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
TriSalus Life Sciences	-62.59%	N/A	-64.47%

CeriBell has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

In the previous week, CeriBell and CeriBell both had 6 articles in the media. CeriBell's average media sentiment score of 0.65 beat TriSalus Life Sciences' score of -0.13 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CeriBell presently has a consensus target price of $27.00, suggesting a potential upside of 14.26%. TriSalus Life Sciences has a consensus target price of $10.20, suggesting a potential upside of 151.23%. Given TriSalus Life Sciences' higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

CeriBell beats TriSalus Life Sciences on 9 of the 16 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, TriSalus Life Sciences had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 2 mentions for Anbio Biotechnology. TriSalus Life Sciences' average media sentiment score of -0.13 beat Anbio Biotechnology's score of -0.63 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anbio Biotechnology has higher earnings, but lower revenue than TriSalus Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	77.52	$6.40M	N/A	N/A
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A

Anbio Biotechnology has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
TriSalus Life Sciences	-62.59%	N/A	-64.47%

Anbio Biotechnology has a beta of 5.31, indicating that its stock price is 431% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

TriSalus Life Sciences has a consensus price target of $10.20, indicating a potential upside of 151.23%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

TriSalus Life Sciences beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Beta Bionics?

TriSalus Life Sciences (NASDAQ:TLSI) and Beta Bionics (NASDAQ:BBNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Beta Bionics had 32 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 38 mentions for Beta Bionics and 6 mentions for TriSalus Life Sciences. Beta Bionics' average media sentiment score of 0.05 beat TriSalus Life Sciences' score of -0.13 indicating that Beta Bionics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	33 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics has a net margin of -61.31% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
Beta Bionics	-61.31%	-26.30%	-23.25%

TriSalus Life Sciences has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A
Beta Bionics	$100.25M	7.91	-$73.20M	-$1.65	N/A

TriSalus Life Sciences currently has a consensus price target of $10.20, suggesting a potential upside of 151.23%. Beta Bionics has a consensus price target of $23.50, suggesting a potential upside of 33.30%. Given TriSalus Life Sciences' higher possible upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.64

TriSalus Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.39, suggesting that its stock price is 239% more volatile than the broader market.

2.6% of TriSalus Life Sciences shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Beta Bionics beats TriSalus Life Sciences on 10 of the 17 factors compared between the two stocks.

Get TriSalus Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSI vs. The Competition

Export

Metric	TriSalus Life Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$254.31M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-3.12	25.57	274.15	26.16
Price / Sales	5.55	83.25	635.98	113.06
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	-5.97	5.93	11.21	6.34
Net Income	-$39.23M	$146.18M	$3.50B	$381.90M
7 Day Performance	-6.02%	-0.38%	-0.90%	-1.41%
1 Month Performance	-13.62%	-2.02%	-4.44%	-3.48%
1 Year Performance	-6.02%	5.08%	6.96%	1.16%

TriSalus Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSI TriSalus Life Sciences	2.2525 of 5 stars	$4.06 -1.7%	$10.20 +151.2%	-8.1%	$254.31M	$45.08M	N/A	102
ENOV Enovis	3.6499 of 5 stars	$18.22 -1.3%	$40.38 +121.6%	-43.4%	$1.06B	$2.30B	N/A	7,802	News Coverage Analyst Downgrade
PRCT PROCEPT BioRobotics	3.742 of 5 stars	$18.31 +0.5%	$25.09 +37.0%	-47.2%	$1.05B	$337.34M	N/A	888	Positive News Analyst Upgrade
CBLL CeriBell	2.483 of 5 stars	$24.44 -1.7%	$24.40 -0.1%	+84.3%	$937.82M	$89.06M	N/A	300
NNNN Anbio Biotechnology	0.5268 of 5 stars	$6.18 +0.2%	N/A	N/A	$888.53M	$8.65M	N/A	27	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSI) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. ENOV, PRCT, CBLL, NNNN, and BBNX

How does TriSalus Life Sciences compare to Enovis?

Summary

How does TriSalus Life Sciences compare to PROCEPT BioRobotics?

Summary

How does TriSalus Life Sciences compare to CeriBell?

Summary

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Summary

How does TriSalus Life Sciences compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. ENOV, PRCT, CBLL, NNNN, and BBNX

How does TriSalus Life Sciences compare to Enovis?

Which has better valuation and earnings, ENOV or TLSI?

Do analysts prefer ENOV or TLSI?

Is ENOV or TLSI more profitable?

Does the media favor ENOV or TLSI?

Which has more volatility and risk, ENOV or TLSI?

Do insiders & institutionals hold more shares of ENOV or TLSI?

Summary

How does TriSalus Life Sciences compare to PROCEPT BioRobotics?

Does the media refer more to TLSI or PRCT?

Which has more volatility & risk, TLSI or PRCT?

Which has better earnings & valuation, TLSI or PRCT?

Do institutionals and insiders have more ownership in TLSI or PRCT?

Is TLSI or PRCT more profitable?

Do analysts prefer TLSI or PRCT?

Summary

How does TriSalus Life Sciences compare to CeriBell?

Which has higher earnings & valuation, CBLL or TLSI?

Do insiders and institutionals hold more shares of CBLL or TLSI?

Is CBLL or TLSI more profitable?

Which has more volatility & risk, CBLL or TLSI?

Does the media favor CBLL or TLSI?

Do analysts rate CBLL or TLSI?

Summary

How does TriSalus Life Sciences compare to Anbio Biotechnology?

Does the media prefer NNNN or TLSI?

Which has stronger earnings & valuation, NNNN or TLSI?

Is NNNN or TLSI more profitable?

Which has more risk & volatility, NNNN or TLSI?

Do analysts recommend NNNN or TLSI?

Do institutionals & insiders have more ownership in NNNN or TLSI?

Summary

How does TriSalus Life Sciences compare to Beta Bionics?

Does the media refer more to TLSI or BBNX?

Is TLSI or BBNX more profitable?

Which has stronger valuation and earnings, TLSI or BBNX?

Do analysts prefer TLSI or BBNX?

Which has more volatility and risk, TLSI or BBNX?

Do insiders and institutionals believe in TLSI or BBNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools